Teva Pharmaceutical的部门与Prestige Bizarma达成许可协议，将Tuznue在欧洲大部分市场商业化

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:AND) entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets.

Tuznue® is approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received the European Commission (EC) marketing authorization for Tuznue® in September 2024.

Under the terms of the license and supply agreement, Teva secured rights to market and distribute Tuznue® in a majority of European markets, leveraging its extensive commercial network and proven expertise in biosimilars. Prestige Biopharma will be responsible for production and supply through its EU-GMP-certified, high-tech facilities equipped with advanced single-use technology.